Medicines Development for Global Health & Atticus Medical enroll first patient in Phase 2b study of moxidectin in scabies

Medicines Development for Global Health & Atticus Medical enroll first patient in Phase 2b study of moxidectin in scabies

In November 2023, Medicines Development for Global Health supported by Atticus Medical enrolled the first participant in a Phase 2b clinical study of moxidectin in patients with scabies. The multi-national, randomized, double-blind, placebo-controlled study (protocol number MDGH‑MOX‑2002; NCT05875441) is designed to evaluate the efficacy and safety of 8, 16 or 32 mg of moxidectin compared to placebo in adults with scabies. Recruitment is on-going, with sites open or soon to open in Honduras, the Dominican Republic, El Salvador, Puerto Rico and the United States. This study is being conducted in partnership with, and funded by, Atticus Medical, which owns the rights to moxidectin in high-income countries with these development activities benefiting low-, middle- and high-income countries.

Moxidectin is an investigational medicine being developed as a potential single dose oral treatment for scabies. If successful, moxidectin has the potential to dramatically improve the scabies treatment paradigm as existing topical treatments are cumbersome whilst oral treatments are not approved in all jurisdictions. All current treatment options typically require more than one dose for the best outcomes.

Mark Sullivan AO, Managing Director of Medicines Development for Global Health said “We are excited to have begun the next phase of development of moxidectin as a potential treatment for scabies. Moxidectin is approved for river blindness and under development for the treatment of 5 further parasitic diseases that impact more than a billion people globally, and it has the potential to become one of the most transformational medicines in global health.”

-End